




PHERECYDES
PHARMA



THE REVOLUTIONARY
BIO NANO COMPANY
USING RECOMBINANT
PHAGES FOR BUSINESS
PURPOSES

Corporate Presentation

1. Shareholders

- Venture capital
 - Fond Sécurité and Financière de Brienne
 - Investment € 1.15 million: first round
 - ACE Management
 - 7 investment funds
 - Managing € 300 million in capital
 - For industrial and financial leaders



FOUNDED BY INDUSTRY
ENTREPRENEURS
AND TRUSTED BY
PRIVATE EQUITY

- Private company
 - BioModeling Systems S.A.S Company
 - Manuel Géa and François Iris
 - Predictive integrated biology



Discovered both genuine
concepts behind TAPE &
Ab-Accus patents

1. Phages


- Bacteria natural predators
- Discovered in 1917
- High bacterial specificity



Félix d'Hérelle



2. Global approach




Applications

3. Our anti infective phage strategy...

Host recognition is based on tail fibers.


- Modify protein tail fibers
- Create huge diversities of tail proteins
- Design banks of phages that recognize:
 - Different bacterial strains
 - Diverse bacterial species
- Select phage variants to control:
 - Antibiotic multi resistant bacterial strains
 - Phage resistant bacteria
 - Emerging bacteria



We create phage variants against specific gram- bacteria through targeted accelerated protein evolution

Application

1. ...offers a way to fight resistance



Using a mixture of phage variants will highly reduce the risk of bacterial resistance occurrence.
If it happens, we already have the next phage to control it

Potential applications




3. But TAPE has more purposes !

A variety of applications

Therapeutic antibody affinity increase

Bioconversion/biocatalysis process optimization

Industrial enzymatic reaction enhancement



Wider use than just phage engineering:
a process to optimize high value proteins

4. Theranostic

Diagnostic using phage variant gallery

For E. coli infections as a start

To determine patient strain profile

To check phage killing effect

STEP 1

Theranostic

STEP 2

Phage therapy using a phage cocktail

For personalized medicine


Using a variant phage mix to reduce phage resistance risk

Including a way to combat phage resistance occurrence

Strategy

4. When ?

Phage diagnostic gallery 1st sales expected early 2012 for *E. coli*



Variant phages for other bacterial strains

Phage therapy in 2 different infectious domains for 2015

Conclusion

5. Contacts



- Address

Pherecydes Pharma
Biocitech
102 avenue Gaston Roussel
93230 Romainville - France

- Contacts

Business development: Jérôme GABARD

Jerome.gabard@pherecydes-pharma.com

Investors : Delphine DINARD (ACE Management)

del@acemanagement.fr

R&D: Flavie POUILLOT

flavie.pouillot@pherecydes-pharma.com